{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:35:04Z","timestamp":1794663304809,"version":"4.9.1"},"reference-count":39,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1080\/17425255.2024.2415295","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T08:14:02Z","timestamp":1729066442000},"page":"161-172","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2312-7050","authenticated-orcid":false,"given":"Catia","family":"Marzolini","sequence":"first","affiliation":[{"name":"University Hospital of Lausanne and University of Lausanne","place":["Lausanne, Switzerland"]},{"name":"University Hospital of Basel and University of Basel","place":["Basel, Switzerland"]},{"name":"University of Liverpool","place":["Liverpool, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gibbons","sequence":"additional","affiliation":[{"name":"University of Liverpool","place":["Liverpool, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Seddon","sequence":"additional","affiliation":[{"name":"University of Liverpool","place":["Liverpool, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[{"name":"University of Liverpool","place":["Liverpool, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"Sunlenca prescribing information. Gilead sciences 2022. [cited 2024 Jul]. Available from: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/sunlenca\/sunlenca_pi.pdf"},{"key":"e_1_3_4_4_1","unstructured":"Sunlenca summary of product characteristics. Gilead sciences 2022. [cited 2024 Jul]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2022\/20220817156456\/anx_156456_en.pdf"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2443-1"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/life11020100"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000713"},{"key":"e_1_3_4_9_1","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Daar E","year":"2020","unstructured":"Daar E, McDonald C, Crofoot G, et al. Dose-response relationship of subcutaneous long-acting HIV capsid inhibitor GS-6207. In: Conference on Retroviruses and Opportunistic Infections; Boston; 2020 Mar 8\u201310. abstract 469."},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa060"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02057-20"},{"key":"e_1_3_4_12_1","volume-title":"International AIDS Conference","author":"Shaik NA","year":"2023","unstructured":"Shaik NA, Bellanti F, Pollireddy K, et al. Comparison of long-acting lenacapavir phase 2\/3 regimen vs simplified regimen using population-pk analysis and simulation. In: International AIDS Conference; Brisbane; 2023 Jul 23\u201326. abstract EPB0230."},{"key":"e_1_3_4_13_1","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Shaik NA","year":"2023","unstructured":"Shaik NA, Bellanti F, Comisar C, et al. Population-pk analysis to guide dosing window following lenacapavir SC administration. In: Conference on Retroviruses and Opportunistic Infections; Boston; 2023 Feb 19\u201323. abstract 504."},{"key":"e_1_3_4_14_1","volume-title":"International AIDS Conference","author":"Singh R","year":"2023","unstructured":"Singh R, Shaik NA, Bellanti F, et al. Recommendations for missed oral lenacapavir loading doses using population-pharmacokinetics-based simulations. In: International AIDS Conference; Brisbane; 2023 Jul 23\u201326. abstract TUPEB14."},{"key":"e_1_3_4_15_1","volume-title":"International AIDS Conference","author":"Jogiraju V","year":"2023","unstructured":"Jogiraju V, Shelton M, Shaik N, et al. Pharmacokinetic bridging with oral lenacapavir for missed subcutaneous Q6M dosing. In: International AIDS Conference; Brisbane; 2023 Jul 23\u201326. abstract TUPEB07."},{"key":"e_1_3_4_16_1","volume-title":"ID Week Conference","author":"Lat AK","year":"2023","unstructured":"Lat AK, Kim A, Zhang H, et al. Impact of subcutaneous administration sites on the clinical pharmacokinetics of lenacapavir, a long-acting HIV capsid inhibitor: does body site matter? In: ID Week Conference; Boston; 2023 Oct 11\u201315. abstract 1542."},{"key":"e_1_3_4_17_1","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Begley R","year":"2020","unstructured":"Begley R, Rhee M, West SK, et al. PK, food effect, and safety of oral GS6207, a novel HIV-1 capsid inhibitor. In: Conference on Retroviruses and Opportunistic Infections; Boston; 2020 Mar 8\u201311. abstract 470."},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.3c00626"},{"key":"e_1_3_4_19_1","volume-title":"International AIDS Conference","author":"Begley R","year":"2020","unstructured":"Begley R, Lutz J, Rhee M, et al. GS-6207 sustained delivery formulation supports 6-month dosing interval. In: International AIDS Conference; 2020 Jul 6\u201310. virtual. abstract PEBO265."},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01328-1"},{"key":"e_1_3_4_21_1","unstructured":"Begley R Lutz J Dvory-Sobol H et al. Clinical evaluation of drug interactions with oral lenacapavir and probe drugs. CROI 2021 virtual Mar 6\u201310. abstract 89."},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01344-23"},{"key":"e_1_3_4_23_1","unstructured":"HIV Drug Interactions. [cited 2024 Jul]. Available from: https:\/\/www.hiv-druginteractions.org"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173509"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00717-18"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12541"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12075"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0637-6"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/21556660.2013.785413"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-023-00833-9"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01797-5"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1515\/dmdi-2014-0005"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v68n1011"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00195913"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050548"},{"key":"e_1_3_4_36_1","unstructured":"Stendra highlights of prescribing information. Vivus 2022. [cited 2024 Jul]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202276s000lbl.pdf"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab412"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12399"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae060"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16006"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac901"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2024.2415295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T03:59:28Z","timestamp":1738382368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2024.2415295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1080\/17425255.2024.2415295"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2024.2415295","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}